iACT Stealth is designed to work in tandem with Pluristyx's FailSafe (R) technology. FailSafe's drug-inducible safety feature acts as a genetic "kill switch," allowing for the selective removal of any ...
Advances in iPSC technology and in vivo reprogramming are expanding the possibilities for cell therapy. Explore the science ...
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its ...
Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader ...
PHILADELPHIA--(BUSINESS WIRE)--Accelerated Biosciences and Stemmatters are thrilled to announce their strategic partnership aimed at co-developing and co-marketing human induced pluripotent stem cells ...
Avoiding many of the pitfalls associated with conventional iPSC reprogramming methods that can introduce genetic instability, PSXi013 has been reprogrammed using our state-of-the-art, footprint-free ...
iXCells Biotechnologies USA, announced the delivery of over 500 characterized induced pluripotent stem cell (iPSC) lines as part of a multi-year collaboration with a global biotechnology company. The ...
Scientists at the Centre for Genomic Regulation (CRG) and other institutions have published details of a treatment that accelerates the production of female induced pluripotent stem cells (iPSCs) from ...
World-renowned stem cell scientists will gather in Kyoto, Japan for the International Society for Stem Cell Research (ISSCR) International Symposium, 20 Years of iPSC Discovery: A Celebration and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results